<DOC>
	<DOCNO>NCT00074321</DOCNO>
	<brief_summary>Drugs use chemotherapy , irinotecan , oxaliplatin , capecitabine , work different way stop tumor cell divide stop grow die . Combining one chemotherapy drug may kill tumor cell . This phase I trial study side effect best dose irinotecan , oxaliplatin , capecitabine treat patient unresectable solid tumor .</brief_summary>
	<brief_title>Irinotecan , Oxaliplatin , Capecitabine Treating Patients With Unresectable Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . To define maximally tolerate dose combination CPT-11 ( irinotecan hydrochloride ) , oxaliplatin , capecitabine three different population , base UDP glucuronosyltransferase 1 family , polypeptide A1 ( UGT1A1 ) genotype ( 6/6 , 6/7 , 7/7 ) . II . To identify activity treatment combination patient metastatic cancer . III . To examine difference toxicity profile , especially pertain hematologic gastrointestinal ( GI ) , maximally tolerate dose combination CPT-11 , oxaliplatin capecitabine respect UGT1A1 haplotype . IV . Examine effect UGT1A1 genotype pharmacokinetics CPT-11 metabolite . OUTLINE : This dose-escalation study . Patients stratify accord UGT1A1 genotype ( 6/6 vs 6/7 [ close accrual 8/24/06 ] vs 7/7 ) . Patients receive irinotecan hydrochloride intravenously ( IV ) 90 minute oxaliplatin IV 2 hour day 1 capecitabine orally ( PO ) twice daily ( QD ) day 2-15 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan hydrochloride , oxaliplatin , capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 6-10 patient ( total 12 patient ) receive treatment dose . After completion study treatment , patient follow 3 month . PROJECTED ACCRUAL : A total 54-84 patient ( 12-22 stratum I , 18-28 stratum II [ close accrual 8/24/06 ] , 24-34 stratum III ) accrue study within approximately 4.4 year .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm solid tumor know standard therapy potentially curative capable extend life expectancy Unresectable disease Willing provide biologic specimens determine UGT1A1 genotype No CNS metastases Prior CNS metastases allow provided patient treat surgery and/or radiotherapy stable 8 week Performance status ECOG 02 At least 12 week Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Bilirubin great upper limit normal ( ULN ) patient 6/6 UGT1A1 genotype ( 1.5 time ULN patient 6/7 [ close accrual 8/24/06 ] 7/7 UGT1A1 genotype ) AST great 3 time ULN ( 5 time ULN liver involvement ) Creatinine great 1.5 time ULN No New York Heart Association class III IV heart disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergy platinum compound , irinotecan , antiemetics antidiarrheal appropriate administration study therapy No uncontrolled infection No seizure disorder No peripheral neuropathy grade 2 great More 4 week since prior biologic therapy More 4 week since prior immunotherapy No concurrent immunotherapy No concurrent prophylactic colonystimulating factor therapy More 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy See Disease Characteristics More 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy See Disease Characteristics No concurrent investigational therapy No concurrent sorivudine , brivudine , lamivudine , stavudine No concurrent enrollment study involve pharmacologic agent symptom control therapeutic intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>